SHIFT AI Newsroom · GLOBAL
Tirzepatide's Link to Atrial Fibrillation in Adults with Overweight or Obesity Under Investigation
Researchers have conducted an updated meta-analysis of randomized controlled trials to explore the relationship between tirzepatide and the incidence of atrial fibrillation in adults with overweight or obesity.
An updated meta-analysis of randomized controlled trials has been published, exploring the incidence of atrial fibrillation in adults with overweight or obesity taking tirzepatide. The study aims to provide insight into the potential risks associated with this treatment.
What this means in the UK
This research is relevant to the UK as it may inform future treatment decisions and guidelines for managing overweight and obesity, as well as the potential risks associated with tirzepatide.
Known facts
- Tirzepatide is being investigated for its potential link to atrial fibrillation in adults with overweight or obesity.